160 related articles for article (PubMed ID: 8744560)
1. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody.
Galili U; Repik PM; Anaraki F; Mozdzanowska K; Washko G; Gerhard W
Vaccine; 1996 Mar; 14(4):321-8. PubMed ID: 8744560
[TBL] [Abstract][Full Text] [Related]
2. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.
Galili U
Springer Semin Immunopathol; 1993; 15(2-3):155-71. PubMed ID: 7504839
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U
J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270
[TBL] [Abstract][Full Text] [Related]
4. Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model.
Repik PM; Strizki JM; Galili U
J Gen Virol; 1994 May; 75 ( Pt 5)():1177-81. PubMed ID: 7513744
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose.
LaTemple DC; Henion TR; Anaraki F; Galili U
Cancer Res; 1996 Jul; 56(13):3069-74. PubMed ID: 8674064
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody.
Henion TR; Gerhard W; Anaraki F; Galili U
Vaccine; 1997 Aug; 15(11):1174-82. PubMed ID: 9286041
[TBL] [Abstract][Full Text] [Related]
7. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
Galili U
Immunol Cell Biol; 2005 Dec; 83(6):674-86. PubMed ID: 16266320
[TBL] [Abstract][Full Text] [Related]
8. Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
Galili U
Med Res Arch; 2021 Jul; 9(7):. PubMed ID: 34853815
[TBL] [Abstract][Full Text] [Related]
9. The alpha-galactosyl epitope on human normal and autoimmune thyroid cells.
Thall A; Etienne-Decerf J; Winand RJ; Galili U
Autoimmunity; 1991; 10(2):81-7. PubMed ID: 1723633
[TBL] [Abstract][Full Text] [Related]
10. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.
Galili U
Immunology; 2013 Sep; 140(1):1-11. PubMed ID: 23578170
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of monoclonal antibodies to a synthetic peptide of influenza haemagglutinin on the processing and presentation of viral antigens to class II-restricted T-cell clones.
Mills KH
Immunology; 1988 Nov; 65(3):365-71. PubMed ID: 2463222
[TBL] [Abstract][Full Text] [Related]
12. alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli.
Galili U; Anaraki F
Glycobiology; 1995 Dec; 5(8):775-82. PubMed ID: 8720075
[TBL] [Abstract][Full Text] [Related]
13. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
14. Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells.
Winand RJ; Anaraki F; Etienne-Decerf J; Galili U
J Immunol; 1993 Oct; 151(7):3923-34. PubMed ID: 8104224
[TBL] [Abstract][Full Text] [Related]
15. Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Galili U; Chen ZC; DeGeest K
Gynecol Oncol; 2003 Jul; 90(1):100-8. PubMed ID: 12821349
[TBL] [Abstract][Full Text] [Related]
16. Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Taniyama K; Kamiike W; Mori M; Doki Y
Cancer Sci; 2013 Mar; 104(3):282-90. PubMed ID: 23240661
[TBL] [Abstract][Full Text] [Related]
17. Individual class II-restricted antigenic determinants of the same protein exhibit distinct kinetics of appearance and persistence on antigen-presenting cells.
Eisenlohr LC; Gerhard W; Hackett CJ
J Immunol; 1988 Oct; 141(8):2581-4. PubMed ID: 2459219
[TBL] [Abstract][Full Text] [Related]
18. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
19. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
